Compare SHBI & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHBI | AURA |
|---|---|---|
| Founded | 1876 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.4M | 797.5M |
| IPO Year | 1997 | 2021 |
| Metric | SHBI | AURA |
|---|---|---|
| Price | $23.10 | $7.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $19.17 | ★ $20.00 |
| AVG Volume (30 Days) | 138.5K | ★ 825.7K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | ★ 34.85 | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $20,853,000.00 | N/A |
| Revenue This Year | $8.97 | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | $21.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.93 | $4.73 |
| 52 Week High | $24.89 | $9.54 |
| Indicator | SHBI | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 44.54 |
| Support Level | $22.47 | $6.65 |
| Resistance Level | $23.12 | $7.83 |
| Average True Range (ATR) | 0.49 | 0.35 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 65.83 | 21.27 |
Shore Bancshares Inc is a financial holding company based in the United States. Through its subsidiaries, it provides consumer and commercial banking products and services, as well as secondary mortgage lending, trust, wealth management, and financial planning services. The group caters to both business and individual clients, offering checking, savings, certificates of deposit, and overnight investment sweep accounts; commercial lending services, including secured and unsecured loans, working capital loans, lines of credit, etc; and safe deposit boxes, debit cards, telephone banking, and other financial products and services.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.